UBS Group’s Envoy Medical COCH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.3K Sell
4,738
-14,346
-75% -$102K ﹤0.01% 8038
2026
Q2
$151K Buy
19,084
+12,038
+171% +$81.7K ﹤0.01% 6954
2026
Q1
$46.9K Buy
7,046
+4,504
+177% +$30.7K ﹤0.01% 7408
2025
Q4
$16.8K Buy
2,542
+132
+5% +$1.04K ﹤0.01% 7904
2025
Q3
$18.7K Buy
2,410
+1,003
+71% +$13.6K ﹤0.01% 8196
2025
Q2
$20K Sell
1,407
-1,249
-47% -$18.3K ﹤0.01% 8440
2025
Q1
$34.5K Buy
2,656
+1,727
+186% +$25.3K ﹤0.01% 7854
2024
Q4
$13.3K Buy
+929
New +$21.1K ﹤0.01% 8148
2024
Q3
– Sell
-604
Closed -$14.3K – 9561
2024
Q2
$14.3K Buy
+604
New +$22.5K ﹤0.01% 7523
2023
Q1
– Sell
-101
Closed -$10.1K – 9680
2022
Q4
$10.1K Buy
101
+64
+173% +$6.36K ﹤0.01% 8566
2022
Q3
$4K Sell
37
-58
-61% -$5.7K ﹤0.01% 9344
2022
Q2
$9K Hold
95
– – ﹤0.01% 8122
2022
Q1
$9K Buy
95
+2
+2% +$195 ﹤0.01% 8535
2021
Q4
$9K Sell
93
-91
-49% -$8.88K ﹤0.01% 8890
2021
Q3
$18K Buy
184
+44
+31% +$4.26K ﹤0.01% 7269
2021
Q2
$14K Buy
+140
New +$13.6K ﹤0.01% 7699

Other funds holding COCH

UBS Group's COCH Position: Q3 2026 in Review

UBS Group reduced its Envoy Medical (COCH) stake by 75% in Q3 2026, selling an estimated $102K and leaving 4,738 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #8038.

UBS Group first reported a position in COCH in Q2 2021 and has held it in 16 quarters since. The position peaked at $151K in Q2 2026. 12 funds tracked by Wall St. Rank hold COCH as of Q3 2026.

  • UBS Group held 4,738 shares of Envoy Medical worth $32.3K as of Q3 2026.
  • UBS Group sold 14,346 Envoy Medical shares in Q3 2026, an estimated $102K.
  • Envoy Medical made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8038 holding.
  • UBS Group first reported a position in Envoy Medical in Q2 2021 and has held it in 16 quarters since.
  • UBS Group's Envoy Medical position peaked at $151K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held Envoy Medical as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.